Introduction
============

Ovarian cancer is a malignancy with one of the poorest prognoses, which was reported to rank as the fifth leading cause of cancer in women, with \~140,200 deaths annually worldwide ([@b1-mmr-16-03-3155]). Epithelial ovarian cancer (EOC) is one of the most frequently observed types of gynecological cancer, accounting for 85--90% of cases of ovarian cancer ([@b2-mmr-16-03-3155]). EOC is commonly diagnosed at an advanced stage, resulting in a poor 5-year overall survival rate of 25--30% ([@b3-mmr-16-03-3155]). The main reasons for the poor prognosis lie in the difficult to identify clinical features, early lymph metastasis and common recurrence. In addition, EOC presents with a variety of clinical manifestations, genetic mutations and tumor morphologies, which add further difficulty to the diagnosis and treatment ([@b4-mmr-16-03-3155]).

Carboplatin \[diammine (1,1-cyclobutanedicarboxylato) platinum (II)\] is one of the most promising second generation platinum compounds. In clinical trials, carboplatin has been demonstrated to be as active, however exhibits less nephrotoxicity and neurotoxicity than cisplatin in previously untreated patients with advanced ovarian cancer ([@b5-mmr-16-03-3155]). Despite the initially high response rate to carboplatin, the relapse rate in ovarian cancer is high and numerous patients will experience recurrence within 6 months, which leads to no improvement in the long-term survival rate ([@b6-mmr-16-03-3155]). Platinum resistance, which predominantly includes carboplatin resistance and cisplatin resistance, is considered as the main reason for the unsatisfactory curative effect, and has led to widespread concerns in EOC ([@b7-mmr-16-03-3155],[@b8-mmr-16-03-3155]). Peters *et al* ([@b9-mmr-16-03-3155]) identified that carboplatin-resistant vs. -sensitive ovarian cancer cells differentially expressed genes (DEGs) were associated with apoptosis, cell-cell communication, cell adhesion, DNA repair and cell proliferation. However, fewer biomarkers were identified of carboplatin resistance and the specific mechanism remains unclear. Therefore, further potential key genes associated with effects of carboplatin on EOS are urgently required in order to confirm, and further explore the mechanisms of carboplatin resistance. In the present study, carboplatin-induced sequential gene expression changes in EOS were identified and analyzed via microarray analysis, in order to screen out certain biomarkers or pathways of EOS that may be involved in the mechanism of carboplatin resistance.

Materials and methods
=====================

### Microarray data

The expression profile of GSE13525 ([@b10-mmr-16-03-3155]) was downloaded from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)). There were 12 EOC cell samples in this profile, including 6 samples treated with carboplatin at 24, 30 and 36 h, with 2 samples at every time point (case group), and 6 samples treated with phosphate-buffered saline at the same time points (control group). Here, EOC cell samples were 36M2 cell lines, which were sensitive to carboplatin. Detection of this profile was performed based on the platform of GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA).

### Data pre-processing

For the expression profile, the original data were converted into a recognizable format with the affy package ([@b11-mmr-16-03-3155]). The method of Robust Multi-array Average ([@b12-mmr-16-03-3155]) was used for normalization and logarithmic conversion. If multi-probes corresponded to a gene symbol, the average value was regarded as the gene expression value.

### Identification and comparison of DEGs

Subsequent to the data pre-processing, DEGs were selected out using Limma ([@b13-mmr-16-03-3155]) package according to the criteria: P\<0.05, \|log2 (fold-change)\|\>0.05. In the current study, 3 sets of DEGs were obtained, including DEGs in EOC cell samples treated with carboplatin compared with the control group at 24, 30 and 36 h, respectively, which were separately recorded as DEG-24, DEG-30 and DEG-36. The 3-set DEGs were compared and the overlapped DEGs were screened out. In addition, the cluster analysis of the overlapped genes was conducted.

### Functional and pathway enrichment analysis

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the overlapped DEGs were performed via the Database for Annotation, Visualization and Integrated Discovery (<http://david.abcc.ncifcrf.gov/>) ([@b14-mmr-16-03-3155]). The GO terms and the KEGG pathways were screened out with the criteria P\<0.05.

### Construction of the protein-protein interaction network and the survival curve

The interactions among the overlapped genes were explored with the Search Tool for the Retrieval of Interacting Genes/Proteins database ([string-db.org](string-db.org)) ([@b15-mmr-16-03-3155]). Subsequently, the protein-protein interaction (PPI) network was constructed by Cytoscape software ([@b16-mmr-16-03-3155]). Certain critical nodes with higher degrees were analyzed, and the 'degree' represented the connections with other nodes. In addition, the interactions between the expression values of the critical nodes and the survival period were evaluated with the KMplot software version 4.7.2 (ChinaUnix; [www.chinaunix.net](www.chinaunix.net)), and the survival curves were plotted. In addition, correlation analysis between some important nodes and the outcome of EOC was performed.

Results
=======

### DEGs and overlaps

A total of 170,605 and 1,043 DEGs were obtained in DEG-24 DEG-30 and DEG-36, and the Venn diagram is presented in [Fig. 1](#f1-mmr-16-03-3155){ref-type="fig"}. It was clearly identified that there were 110 overlaps in the 3-set DEGs, and 40 out of the 110 overlaps (arbitrarily selected) were presented in [Table I](#tI-mmr-16-03-3155){ref-type="table"}. In addition, the heatmap of the overlaps was presented in [Fig. 2](#f2-mmr-16-03-3155){ref-type="fig"}.

### GO terms and KEGG pathways

The overlaps were enriched in 77 GO terms and 3 KEGG pathways \[p53 signaling pathway, cell cycle and mitogen-activated protein kinase (MAPK) signaling pathway\], and the top 10 most significant GO terms were exhibited in [Table II](#tII-mmr-16-03-3155){ref-type="table"}.

### The PPI network and survival curves

The PPI network of the overlaps was established and exhibited in [Fig. 3](#f3-mmr-16-03-3155){ref-type="fig"}, including 152 interaction pairs. The top 30 nodes with high degrees were presented in [Table III](#tIII-mmr-16-03-3155){ref-type="table"} (e.g. *c-Jun* and *CCNB1*). In addition, the survival curves were drawn to demonstrate the associations between the gene expression levels and the prognosis of EOC for *c-Jun* and *CCNB1*, respectively. The two survival curves were presented in [Figs. 4](#f4-mmr-16-03-3155){ref-type="fig"} and [5](#f5-mmr-16-03-3155){ref-type="fig"}. It was clear that the high or low expression probability of *c-Jun* and *CCNB1* was negatively associated with the survival time of patients, that is, the abnormal expression probability of *c-Jun* and *CCNB1* was positively correlated with a poor outcome of EOC.

Discussion
==========

Platinum drugs, such as cisplatin and carboplatin, have been most frequently used for treatment of ovarian cancer. However, platinum resistance has severely limited its efficacy, which is a major clinical problem requiring a solution. In the present study, the carboplatin-induced sequential genes expression changes of EOC were analyzed, and 3 KEGG pathways of overlaps were obtained, including the p53 signaling pathway, cell cycle and MAPK signaling pathway. Certain studies have indicated that these pathways were involved in the platinum resistance of ovarian cancer. One study reported that chaetoglobosin K induced G~2~ cell cycle arrest through a p53-dependent pathway in cisplatin-resistant ovarian cancer cells ([@b17-mmr-16-03-3155]). An additional study drew a similar conclusion that theaflavin-3, 3′-digallate induced G~2~ cell cycle arrest through the protein kinase B/MDM2/p53 pathway in cisplatin-resistant ovarian cancer cells ([@b18-mmr-16-03-3155]). Meng *et al* ([@b19-mmr-16-03-3155]) hypothesized that ovarian cancer cells expressing *aldehyde dehydrogenase 1 family member A1* may maintain platinum resistance by altered regulation of cell cycle checkpoints and DNA repair network signaling. MAPKs regulate diverse cellular programs including embryogenesis, proliferation, differentiation and apoptosis based on cues derived from the cell surface and the metabolic state and environment of the cell ([@b20-mmr-16-03-3155]). They are activated by dual phosphorylation of threonine and tyrosine in response to a wide array of extracellular stimuli ([@b21-mmr-16-03-3155]). Results of a previous study indicated that cisplatin activated p38 MAPK in all of the cell lines tested, and carboplatin could induce activation of p38 MAPK ([@b22-mmr-16-03-3155],[@b23-mmr-16-03-3155]). The p38 MAPK pathway was considered as a specific target for cisplatin-based therapy with clinical implications. In addition, MEK inhibition could overcome cisplatin resistance conferred the son of sevenless/MAPK pathway activation in squamous cell carcinoma ([@b24-mmr-16-03-3155]). In the present study, the overlapped DEGs were enriched in p53 signaling pathway, cell cycle and the MAPK signaling pathway. Therefore, it was suspected that these three pathways may be involved in the carboplatin resistance of EOC, although further research and clinical verifications were necessary to confirm it.

The PPI network of the overlaps was analyzed, and *c-Jun* and *CCNB1* were the top 4 nodes with the highest degrees ([Table III](#tIII-mmr-16-03-3155){ref-type="table"}). In human ovarian cancer, the overexpression of *fucosyltransferase 1* (*FUT1*) was associated with advanced pathological stages and involved in cell proliferation, migration and invasion ([@b25-mmr-16-03-3155]--[@b27-mmr-16-03-3155]). Gao *et al* ([@b28-mmr-16-03-3155]) reported that *c-Jun* could transcriptionally modulate *FUT1* expression in ovarian cancer, implicating the potential application of *c-Jun* inhibitors for human ovarian cancer therapy. Echevarría-Vargas *et al* ([@b29-mmr-16-03-3155]) reported that the c-Jun N-terminal kinase 1/c-Jun/microRNA-21 pathway contributed to the cisplatin resistance of ovarian cancer cells, and the activation of *c-Jun* was closely associated with the prognosis. In addition, the present study identified that abnormal expression of *c-Jun* was positively correlated with a poor outcome of EOC ([Fig. 4](#f4-mmr-16-03-3155){ref-type="fig"}). Therefore, *c-Jun* may be a potential target for the prognosis of EOC. Similarly, *CCNB1* encoded G~2~/mitotic-specific cyclin-B1, a member of the highly conserved cyclin family, whose members were characterized by a marked periodicity in protein abundance through the cell cycle. As abovementioned, cell cycle may contribute to the carboplatin-resistance of EOC. A previous study suggested that sulforaphane induced cell cycle arrest in the G~2~/M phase via the blockade of *CCNB1/cyclin-dependent kinase 1* in human ovarian cancer cells ([@b30-mmr-16-03-3155]). An additional study observed nuclear *CCNB1* was overexpressed in ovarian tumors and associated with a low potential for malignance, however, this was not the case in EOC. Thus, it is suggested that *CCNB1* may not be suitable targets for EOC treatment ([@b31-mmr-16-03-3155]). The present study indicated that *CCNB1* was differentially expressed in carboplatin-resistant EOC cells, and the differential expression of *CCNB1* was closely associated with the low survival rate ([Fig. 5](#f5-mmr-16-03-3155){ref-type="fig"}). Therefore, *CCNB1* may be a potential marker for the prognosis of EOC, although further investigation into whether different expression levels or different treatments would affect *CCNB1* expression levels in EOC are required.

In conclusion, the results of the current study suggested that *c-Jun* and *CCNB1* may be prognostic biomarkers of EOC, and certain pathways (including p53 signaling pathway, cell cycle and MAPK signaling pathway) may contribute to carboplatin resistance of EOC.
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###### 

40 out of the 110 overlapping DEGs.

  Gene        logFC-24   logFC-30   logFC-36
  ----------- ---------- ---------- ----------
  c-Jun       0.597575   1.328237   1.18567
  ATF3        1.23664    2.04034    2.048266
  MYC         0.897095   1.506238   1.185579
  SMYD3       −0.79469   −0.98629   −0.9974
  SUGCT       −0.7813    −1.11645   −0.83396
  CCNB1       −0.7313    −0.56078   −0.51498
  H3F3A       −0.68925   −0.68752   −0.86869
  ZFHX4-AS1   −0.68093   −0.60716   −0.61631
  SLIT2       −0.67813   −0.85581   −0.76238
  TENM2       −0.65069   −0.82711   −1.25469
  EID2B       −0.64698   −0.52262   −0.61981
  GPC6        −0.6393    −0.95796   −1.33614
  TYRP1       −0.63771   −0.85061   −1.41218
  COX7B2      −0.60476   −0.96575   −1.20234
  CCDC102B    −0.59926   −0.99286   −0.83222
  SLC39A11    −0.58811   −0.80546   −0.8992
  FAM155A     −0.57958   −0.5765    −0.61568
  DIAPH2      −0.57649   −0.60056   −0.74229
  ARL15       −0.57305   −0.57539   −0.95364
  ZNF804A     −0.57214   −0.73618   −1.06175
  RBMS3       −0.56804   −0.72509   −0.66383
  COLEC12     −0.5643    −0.56611   −0.92667
  FAM172A     −0.54727   −0.73332   −0.70188
  FRMPD4      −0.54134   −0.65706   −0.60094
  MROH2A      −0.53617   −0.53163   −0.79999
  CSN3        −0.53327   −0.55616   −0.52556
  TMEM117     −0.52405   −0.78864   −1.25632
  NRXN3       −0.5218    −0.62797   −0.83785
  ALG14       −0.51912   −0.69366   −0.92383
  LINC01279   −0.51733   −0.85673   −1.16606
  SPA17       −0.50974   −0.62461   −0.80034
  RNASE4      −0.50843   −0.63322   −1.26577
  ROBO1       −0.50546   −0.82298   −1.17568
  DLGAP5      −0.50254   −0.62455   −0.62672
  CDH13       −0.50095   −0.80013   −1.29452
  SLC25A25    0.501864   0.517077   0.791164
  RELB        0.504759   1.161993   1.440501
  E2F8        0.508001   0.684447   0.689356
  FAM53C      0.509583   0.939359   0.974481
  NFKBIE      0.525352   1.418745   1.240866

DEGs, differentially expressed genes; logFC-24, the log (fold-change) in DEG-24; logFC-30, the log (fold-change) in DEG-30; logFC-36, the log (fold-change) in DEG-36.

###### 

The top 10 most significant GO terms of the overlapping differentially expressed genes.

  Category      Term                                                                     Count   P-value
  ------------- ------------------------------------------------------------------------ ------- ----------
  GOTERM_CC_5   GO:0005634\~nucleus                                                      45      4.27E-05
  GOTERM_BP_5   GO:0051173\~positive regulation of nitrogen compound metabolic process   14      1.24E-04
  GOTERM_BP_5   GO:0048660\~regulation of smooth muscle cell proliferation                 5     1.72E-04
  GOTERM_BP_5   GO:0031328\~positive regulation of cellular biosynthetic process         14      2.29E-04
  GOTERM_BP_5   GO:0009891\~positive regulation of biosynthetic process                  14      2.64E-04
  GOTERM_BP_5   GO:0043065\~positive regulation of apoptosis                             11      2.68E-04
  GOTERM_BP_5   GO:0043068\~positive regulation of programmed cell death                 11      2.83E-04
  GOTERM_BP_5   GO:0010942\~positive regulation of cell death                            11      2.94E-04
  GOTERM_CC_5   GO:0043231\~intracellular membrane-bounded organelle                     58      3.03E-04
  GOTERM_BP_5   GO:0006355\~regulation of transcription, DNA-dependent                   23      6.52E-04

GO, Gene Ontology.

###### 

The top 30 nodes with higher degrees in the PPI network.

  Gene       Degree
  ---------- --------
  c-Jun      22
  ATF3       21
  MYC        20
  CCNB1      14
  CDC6       13
  DDIT3      13
  IL6        13
  GADD45A    10
  IRF1       10
  FOSL1        9
  IL8          9
  RELB         8
  CEBPG        7
  EDN1         7
  ORC1         7
  GADD45B      6
  KLF4         6
  GDF15        5
  MAFF         5
  PCK2         5
  KLF6         4
  MCM10        4
  ORC6         4
  PMAIP1       4
  PPP1R15A     4
  RASSF1       4
  TNFAIP3      4
  E2F8         3
  EXO1         3
  KIF20A       3

PPI, protein-protein interaction.
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